Replimune Group (NASDAQ:REPL) Trading 8.2% Higher - Time to Buy?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shot up 8.2% during trading on Friday . The company traded as high as $13.03 and last traded at $12.99. 742,437 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 1,046,092 shares. The stock had previously closed at $12.01.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on REPL. BMO Capital Markets increased their target price on shares of Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a research note on Friday, November 22nd. Roth Capital raised Replimune Group to a "strong-buy" rating in a research report on Tuesday, August 27th. Jefferies Financial Group lifted their target price on Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, December 4th. JPMorgan Chase & Co. upped their price target on Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 24th. Finally, HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a research report on Friday, November 22nd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $17.29.

Replimune Group Stock Performance

The stock has a 50 day moving average of $12.25 and a two-hundred day moving average of $10.69. The stock has a market capitalization of $854.53 million, a PE ratio of -4.10 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. Research analysts expect that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares of the company's stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares of the company's stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its holdings in shares of Replimune Group by 12.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock worth $5,313,000 after buying an additional 52,498 shares in the last quarter. LMR Partners LLP grew its stake in Replimune Group by 145.8% in the 3rd quarter. LMR Partners LLP now owns 82,479 shares of the company's stock worth $904,000 after acquiring an additional 48,920 shares during the period. Millennium Management LLC raised its holdings in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock valued at $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of Replimune Group by 282.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company's stock worth $650,000 after purchasing an additional 53,313 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in shares of Replimune Group by 63.2% during the 2nd quarter. Acadian Asset Management LLC now owns 185,516 shares of the company's stock worth $1,668,000 after purchasing an additional 71,867 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.